Transcatheter arterial embolization (TAE) of cancer-related bleeding

Background and Objectives: Roughly 10% of cancer patients experience an episode of bleeding. The bleeding severity can range from occasional trivial bleeds to major bleeding. The treatment for the bleeding may vary, depending on the clinical condition and anatomical site, and may include various strategies, among which TAE is a cornerstone of major bleeding management. However, the existing literature on tumor hemorrhages is inconsistent. The objective of this multicenter retrospective cohort study was to evaluate the effectiveness and safety of arterial embolization in the treatment of tumor hemorrhages in patients with solid cancers. Materials and Methods: The data for patients with solid cancers undergoing TAE for the management of tumor hemorrhages from January 2020 to May 2023 were gathered. Results: A total of 92 patients with cancer-related bleeding were treated between January 2020 and May 2023. No bleeding was detected by X-ray angiography (XA) in 12 (13%) cases; therefore, a blind embolization was performed. The most common bleeding site was the liver (21.7%). A total of 66 tumor hemorrhages were spontaneous. The most commonly used embolic agent was polyvinyl alcohol (PVA) particles (30.4%). Technical success was achieved in 82 (89.1%) cases, with an 84.8% clinical success rate related to 14 cases of rebleeding. Proximal embolization was performed for 19 (20.7%) patients. Complications were recorded for 10 (10.9%) patients. The 30-day bleeding-related mortality was 15.2%. The technical success, clinical success, proximal embolization rate, and 30-day rebleeding were worse in the subset of patients undergoing TAE with coils. Conclusions: Transcatheter arterial embolization (TAE) represents a viable and potentially life-saving therapeutic approach in the management of tumor hemorrhages, demonstrating a notable effectiveness and safety. The TAE of bleeding tumors using coils resulted in a higher rate of non-superselective proximal embolization, with a trend toward lower clinical success rates and higher rebleeding episodes

A Multicenter Retrospective Cohort Study Evaluating the Clinical Outcomes of Patients with Coagulopathy Undergoing Transcatheter Arterial Embolization (TAE) for Acute Non-Neurovascular Bleeding

Background and Objectives: Transcatheter arterial embolization (TAE) is the mainstay of treatment for acute major hemorrhage, even in patients with coagulopathy and spontaneous bleeding. Coagulopathy is associated with worsening bleeding severity and higher mortality and clinical failure rates. Furthermore, some unanswered questions remain, such as the definition of coagulopathy, the indication for TAE or conservative treatment, and the choice of embolic agent. This study aims to assess the efficacy and safety of TAE for spontaneous non-neurovascular acute bleeding in patients with coagulopathy. Materials and Methods: This study is a multicenter analysis of retrospectively collected data of consecutive patients with coagulopathy who had undergone, from January 2018 to May 2023, transcatheter arterial embolization for the management of spontaneous hemorrhages. Results: During the study interval (January 2018–May 2023), 120 patients with coagulopathy underwent TAE for spontaneous non-neurovascular acute bleeding. The abdominal wall was the most common bleeding site (72.5%). The most commonly used embolic agent was polyvinyl alcohol (PVA) particles or microspheres (25.0%), whereas coils and gelatin sponge together accounted for 32.5% of the embolic agents used. Technical success was achieved in all cases, with a 92.5% clinical success rate related to 9 cases of rebleeding. Complications were recorded in 12 (10%) patients. Clinical success was significantly better in the group of patients who underwent correction of the coagulopathy within 24 h of TAE. Conclusions: Transcatheter arterial embolization (TAE) is effective and safe for the management of acute non-neurovascular bleeding in patients with coagulopathy. Correction of coagulopathy should not delay TAE and vice versa, as better clinical outcomes were noted in the subgroup of patients undergoing correction of coagulopathy within 24 h of TAE

Skin tears and risk factors assessment: a systematic review on evidence-based medicine

Skin tears represent a common condition of traumatic wounds, which may be encountered in some categories of individuals at the extremes of age, such as infants and the elderly. Despite the high prevalence and cost of these lesions, there has been little investigation into the risk factors that lead to this condition. The aim of this review was to systematically evaluate the main risk factors involved in development of skin tears. We planned to include all the studies dealing with risk factors related to skin tears. Only publications in English were considered. We excluded all the studies that did not properly fit our research question and those with insufficient data. Of the 166 records found, 24 matched our inclusion criteria. After reading the full-text articles, we decided to exclude seven articles because of the following reasons: (1) not responding properly to our research questions and (2) insufficient data; the final set included 17 articles. From a literature search, we found the following main issues related to risk factors, which have been described in detail in this section: age-related skin changes, dehydration, malnutrition, sensory changes, mobility impairment, pharmacological therapies and mechanical factors related to skin care practices. Our findings clearly show that in frail populations (especially infant and elderly), the stratification risk, as a primary prevention strategy, is an effective tool in avoiding the development of chronic wounds. The development and the implementation of prevention strategies based on appropriate knowledge of the risk factors involved and the adoption of correct techniques during skin care practices could reduce or even avoid the onset of skin tears

Novel biomarkers for cardiovascular risk

Cardiovascular disease refers to different diseases involving the heart and/or the arteries and/or the veins. Cardiovascular disease, overall considered, is a notable source of morbidity and mortality worldwide. Therefore, several research studies are dedicated to explore, by means of biomarkers, the possiblity to calculate the cardiovascular risk both for the onset and for the complications of the related clinical manifestations such as coronary artery disease, carotid artery stenosis, peripheral artery disease, arterial aneurysm, chronic venous disease and venous thromboembolism. This review discusses the most updated information in the area of the novel biomarkers related to omics, imaging techniques and clinical data, that may help physicians in order to improve the knowledge and the management of the cardiovascular risk

Percutaneous and surgical femoral access for thoracic endovascular aortic repair using local anesthesia

Background: Nowadays, thoracic endovascular aortic repair (TEVar) is frequently the choice for treatment of thoracic aortic disease because of its less invasiveness. generally, this technique is performed with surgical femoral access with general and epidural anesthesia or with a local anesthesia without spinal catheterization, but there is evidence in literature that suggests the validity of percutaneous approach. The aim of this study is to compare the different techniques according to our personal experience. METhODS: We retrospectively studied patients affected from thoracic aortic disease, in particular those with thoracic aortic aneurysm (Taa) and acute type B aortic dissection (TBAD), in the period September 2002 to December 2016. The first endpoint was the possibility to achieve the femoral access only by local anesthetic injection, and the second endpoint was the comparison between TEVar with femoral exposure and the percutaneous approach. rESuLTS: From September 2002 to December 2016 we have selected a cohort of 45 patients affected by thoracic aortic disease, divided in 22 patients with thoracic aortic aneurism (Taa) and 23 patients with acute type B aortic dissection (TBaD). all patients were treated with TEVar undergoing a local anesthesia. Most of the patients were treated with surgical exposition of the common femoral artery while in 10 eligible patients was used the percutaneous approach. in all cases we had correct placement of the endograft, exclusion of false lumen in case of TBaD and absence of primary endoleak in case of Taa after the procedure. CONCLuSiONS: The use of the local anesthesia, and of the percutaneous approach when possible, have proven to be particularly effective in our casuistry

CBRA: Cardiac biomarkers release analyzer

none10noBackground and objectives: The most advanced technologies and continuous innovations in the medical field require a necessary interaction between the clinical and the engineering world. In this context, software applications are proposed as a bridge between the two scientific fields and, therefore, as powerful tools, easy to use, and with great analytical skills. In this work, we propose CBRA as an innovative software platform, moving towards personalized medicine, which aims to simplify and speed up the triage of patients and support doctors in the diagnostic and prognostic phase. Methods: The computational core of the devised software application consists of a model-based identification algorithm, which enables the reconstruction of the cardiac biomarkers release curves in patients with ST-Elevation Acute Myocardial Infarction (STEMI). Identification and parametric optimization techniques allow the application of the proposed approach to each singular patient: based on a few experimental acquisitions, CBRA can extrapolate several quantitative features of high clinical relevance, thus facilitating and rendering more objective the clinical evaluation and therapeutic choices. A dedicated database to collect and manage patients clinical and personal data, as well as a graphical user interface, provides clinicians and researchers with an intuitive and user-friendly environment. Results: In the following work, we present some examples of the possible applications of CBRA, ranging from the management of the cardiac biomarkers time-series, up to the real analysis of the clinical features that CBRA can extract from the reconstructed curve, such as, e.g., maximum concentration values of biomarkers in the plasma and relative times, in the distinct phases of the acute myocardial infarction, or identification of the time to onset of symptoms. Conclusions: CBRA makes it easy for clinicians to use modeling and parametric identification tools to reconstruct release curves. Furthermore, CBRA provides support to the clinical decision, thanks to its capability to extract information of high clinical relevance, not easily obtainable from the mere visual analysis of experimental samples. Having information about the previously listed clinical parameters could allow, e.g., identify in which stage of AMI the patient is, when She/He goes to the emergency room, with significant benefits in the therapy.noneProcopio A.; De Rosa S.; Montefusco F.; Canino G.; Merola A.; Sabatino J.; Ielapi J.; Indolfi C.; Amato F.; Cosentino C.Procopio, A.; De Rosa, S.; Montefusco, F.; Canino, G.; Merola, A.; Sabatino, J.; Ielapi, J.; Indolfi, C.; Amato, F.; Cosentino, C

PredyCLU: A prediction system for chronic leg ulcers based on fuzzy logic; part II—Exploring the arterial side

Peripheral arterial disease (PAD) and its most severe form, critical limb ischaemia (CLI), are very common clinical conditions related to atherosclerosis and represent the major causes of morbidity, mortality, disability, and reduced quality of life (QoL), especially for the onset of ischaemic chronic leg ulcers (ICLUs) and the subsequent need of amputation in affected patients. Early identification of patients at risk of developing ICLUs may represent the best form of prevention and appropriate management. In this study, we used a Prediction System for Chronic Leg Ulcers (PredyCLU) based on fuzzy logic applied to patients with PAD. The patient population consisted of 80 patients with PAD, of which 40 patients (30 males [75%] and 10 females [25%]; mean age 66.18 years; median age 67.50 years) had ICLUs and represented the case group. Forty patients (100%) (27 males [67.50%] and 13 females [32.50%]; mean age 66.43 years; median age 66.50 years) did not have ICLUs and represented the control group. In patients of the case group, the higher was the risk calculated with the PredyCLU the more severe were the clinical manifestations recorded. In this study, the PredyCLU algorithm was retrospectively applied on a multicentre population of 80 patients with PAD. The PredyCLU algorithm provided a reliable risk score for the risk of ICLUs in patients with PAD

Aortic aneurysms, chronic kidney disease and metalloproteinases

Metalloproteinases (MPs) are proteolytic enzymes involved in extracellular matrix deposi-tion, regulation of cellular signals of inflammation, proliferation, and apoptosis. Metalloproteinases are classified into three families: Matrix-MPs (MMPs), A-Disintegrin-and-Metalloprotease (ADAMs), and the A-Disintegrin-and-Metalloproteinase-with-Thrombospondin-1-like-Domains (ADAMTS). Previous studies showed that MPs are involved in the development of aortic aneurysms (AA) and, concomitantly, in the onset of chronic kidney disease (CKD). CKD has been, per se, associated with an increased risk for AA. The aim of this review is to examine the pathways that may associate MPs with CKD and AA. Several MMPs, such as MMP-2,-8,-9, and TIMP-1 have been shown to damage the AA wall and to have a toxic effect on renal tubular cells, leading to fibrosis. Similarly, ADAM10 and 17 have been shown to degrade collagen in the AA wall and to worsen kidney function via pro-inflammatory stimuli, the impairment of the Renin-Angiotensin-Aldosterone System, and the degradation of structural proteins. Moreover, MMP-2 and-9 inhibitors reduced aneurysm growth and albuminuria in experimental and human studies. It would be important, in the future, to expand research on MPs from both a prognostic, namely, to refine risk stratification in CKD patients, and a predictive perspective, likely to improve prognosis in response to targeted treatments